Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2022

Open Access 28-06-2022 | Adrenocortical Carcinoma | Mini Review

An update on adrenocortical cell lines of human origin

Authors: Sandra Sigala, Elisa Rossini, Andrea Abate, Mariangela Tamburello, Stefan R. Bornstein, Constanze Hantel

Published in: Endocrine | Issue 3/2022

Login to get access

Abstract

Adrenocortical carcinoma (ACC) is a rare, heterogenous and highly malignant disease. Management of ACC is dependent on disease stage with complete surgical resection as the only potentially curative option. However, advanced, un-resectable, metastatic stages and also recurrences often require systemic treatments, which are unfortunately nowadays still unsatisfactory. The scarcity of preclinical models reflecting patient heterogeneities and furthermore drug-resistant phenotypes, has hampered the progress and development of new therapies in recent years. In this review, we provide an overview on the classical models and substantial progress which has been made over the last years in context of this aggressive disease.
Literature
1.
2.
M. Fassnacht et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31(11), 1476–1490 (2020)PubMedCrossRef
3.
A.F. Gazdar et al. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res. 50(17), 5488–5496 (1990)PubMed
4.
A. Dierks et al. Identification of adrenal genes regulated in a potassium-dependent manner. J. Mol. Endocrinol. 45(4), 193–206 (2010)PubMedCrossRef
5.
K.E.M. Ahmed et al. LC-MS/MS based profiling and dynamic modelling of the steroidogenesis pathway in adrenocarcinoma H295R cells. Toxicol. Vitr. 52, 332–341 (2018)CrossRef
6.
M. Kurlbaum et al. Steroidogenesis in the NCI-H295 Cell Line Model is strongly affected by culture conditions and substrain. Exp. Clin. Endocrinol. Diabetes 128(10), 672–680 (2020)PubMedCrossRef
7.
K. Nanba, A.R. Blinder, W.E. Rainey, Primary cultures and cell lines for in vitro modeling of the human adrenal cortex. Tohoku J. Exp. Med. 253(4), 217–232 (2021)PubMedCrossRef
8.
J. Parmar, R.E. Key, W.E. Rainey, Development of an adrenocorticotropin-responsive human adrenocortical carcinoma cell line. J. Clin. Endocrinol. Metab. 93(11), 4542–4546 (2008)PubMedPubMedCentralCrossRef
9.
T. Wang, W.E. Rainey, Human adrenocortical carcinoma cell lines. Mol. Cell Endocrinol. 351(1), 58–65 (2012)PubMedCrossRef
10.
C. Hantel et al. Targeting heterogeneity of adrenocortical carcinoma: evaluation and extension of preclinical tumor models to improve clinical translation. Oncotarget 7(48), 79292–79304 (2016)PubMedPubMedCentralCrossRef
11.
M. Reincke et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J. Clin. Endocrinol. Metab. 78(3), 790–794 (1994)PubMed
12.
E.M. Pinto, K. Kiseljak-Vassiliades, C. Hantel, Contemporary preclinical human models of adrenocortical carcinoma. Curr. Opin. Endocr. Metab. Res. 8, 139–144 (2019)PubMedPubMedCentralCrossRef
13.
S.B.C. Sigala, D. Penton, A. Abate, M. Peitzsch, D. Cosentini, G.A.M. Tiberio, S.R. Bornstein, A. Berruti, C. Hantel, A comprehensive investigation of steroidogenic signaling in classical and new experimental cell models of adrenocortical carcinoma. Cells, 2022. 11
14.
F. Tissier et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 65(17), 7622–7627 (2005)PubMedCrossRef
15.
N.G. Nicolson, R. Korah, T. Carling, Adrenocortical cancer cell line mutational profile reveals aggressive genetic background. J. Mol. Endocrinol. 62(4), 179–186 (2019)PubMedCrossRef
16.
17.
C. Hantel, F. Beuschlein, Xenograft models for adrenocortical carcinoma. Mol. Cell Endocrinol. 421, 28–33 (2016)PubMedCrossRef
18.
M. Doghman et al. Integrative analysis of SF-1 transcription factor dosage impact on genome-wide binding and gene expression regulation. Nucleic Acids Res. 41(19), 8896–8907 (2013)PubMedPubMedCentralCrossRef
19.
M. Doghman et al. Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol. Endocrinol. 21(12), 2968–2987 (2007)PubMedCrossRef
20.
A. Logie et al. Establishment and characterization of a human adrenocortical carcinoma xenograft model. Endocrinology 141(9), 3165–3171 (2000)PubMedCrossRef
21.
T.C. Brown et al. Insulin-like growth factor and SLC12A7 dysregulation: a novel signaling hallmark of non-functional adrenocortical carcinoma. J. Am. Coll. Surg. 229(3), 305–315 (2019)PubMedCrossRef
22.
C. Hantel et al. Liposomal doxorubicin-based treatment in a preclinical model of adrenocortical carcinoma. J. Endocrinol. 213(2), 155–161 (2012)PubMedCrossRef
23.
F. Beuschlein et al. IGF1-R inhibition and liposomal doxorubicin: progress in preclinical evaluation for the treatment of adrenocortical carcinoma. Mol. Cell Endocrinol. 428, 82–88 (2016)PubMedCrossRef
24.
S. Sbiera et al. Mitotane Inhibits Sterol-O-Acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology. 156(11), 3895–3908 (2015)PubMedCrossRef
25.
C. Hantel et al. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model. Endocr. Relat. Cancer 21(3), 383–394 (2014)PubMedCrossRef
26.
S. Jung et al. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma. Endocr. Relat. Cancer 23(10), 825–837 (2016)PubMedCrossRef
27.
A. Hasanovic et al. Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma in vitro and in vivo. Int J. Cancer 143(1), 199–211 (2018)PubMedCrossRef
28.
C. Siebert et al. Heat shock protein 90 as a prognostic marker and therapeutic target for adrenocortical carcinoma. Front Endocrinol. (Lausanne) 10, 487 (2019)CrossRef
29.
R. Liang et al. Targeted gene expression profile reveals CDK4 as therapeutic target for selected patients with adrenocortical carcinoma. Front Endocrinol. (Lausanne) 11, 219 (2020)CrossRef
30.
M. Fragni et al. In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures(). Mol. Cell Endocrinol. 498, 110585 (2019)PubMedCrossRef
31.
K.M. Warde et al. Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC. Endocr. Relat. Cancer 27(6), 361–373 (2020)PubMedCrossRef
32.
A. Abate et al. Cytotoxic effect of trabectedin in human adrenocortical carcinoma cell lines and primary cells. Cancers (Basel) 12(4), (2020)
33.
C. Bothou et al. Novel insights into the molecular regulation of ribonucleotide reductase in adrenocortical carcinoma treatment. Cancers (Basel) 13(16), (2021)
34.
G. Cantini et al. Stimulated expression of CXCL12 in adrenocortical carcinoma by the PPARgamma ligand rosiglitazone impairs cancer progression. J Pers. Med. 11(11), (2021)
35.
E. Rossini et al. Cytotoxic effect of progesterone, tamoxifen and their combination in experimental cell models of human adrenocortical cancer. Front Endocrinol. (Lausanne) 12, 669426 (2021)CrossRef
36.
A. Abate et al. Ribociclib cytotoxicity alone or combined with progesterone and/or mitotane in in vitro adrenocortical carcinoma cells. Endocrinology (2021)
37.
K. Warde et al. Investigating the role of cholesterol and lipid trafficking in mitotane resistance in adrenocortical carcinoma. J. Endocr. Soc. 5(Supplement_1), A70–A70 (2021)PubMedCentralCrossRef
38.
K.K. Rasiah et al. HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer. Mol. Cell Endocrinol. 301(1–2), 89–96 (2009)PubMedCrossRef
39.
H.K. Ko et al. Loss of an androgen-inactivating and isoform-specific HSD17B4 splice form enables emergence of castration-resistant prostate cancer. Cell Rep. 22(3), 809–819 (2018)PubMedPubMedCentralCrossRef
40.
M. Barnard et al. The role of adrenal derived androgens in castration resistant prostate cancer. J. Steroid Biochem Mol. Biol. 197, 105506 (2020)PubMedCrossRef
41.
K. Kiseljak-Vassiliades et al. Development of new preclinical models to advance adrenocortical carcinoma research. Endocr. Relat. Cancer 25(4), 437–451 (2018)PubMedPubMedCentralCrossRef
42.
S. Grisanti et al. Molecular genotyping of adrenocortical carcinoma: a systematic analysis of published literature 2019-2021. Curr. Opin. Oncol. 34(1), 19–28 (2022)PubMedCrossRef
43.
I. Weigand et al. Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. Cell Death Dis. 11(3), 192 (2020)PubMedPubMedCentralCrossRef
44.
K. Kiseljak-Vassiliades et al. Elucidating the role of the maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma. Endocrinology 159(7), 2532–2544 (2018)PubMedPubMedCentralCrossRef
45.
46.
A.G. Maria et al. Inhibition of Aurora kinase A activity enhances the antitumor response of beta-catenin blockade in human adrenocortical cancer cells. Mol. Cell Endocrinol. 528, 111243 (2021)PubMedPubMedCentralCrossRef
47.
J. Lang et al. Development of an Adrenocortical Cancer Humanized Mouse Model to characterize anti-PD1 effects on tumor microenvironment. J. Clin. Endocrinol. Metab. 105(1), (2020)
48.
L.S. Landwehr et al. A novel patient-derived cell line of adrenocortical carcinoma shows a pathogenic role of germline MUTYH mutation and high tumour mutational burden. Eur. J. Endocrinol. 184(6), 823–835 (2021)PubMedCrossRef
49.
50.
M. Fragni et al. In vitro antitumor activity of progesterone in human adrenocortical carcinoma. Endocrine 63(3), 592–601 (2019)PubMedCrossRef
51.
C. Fiorentini et al. Antisecretive and antitumor activity of abiraterone acetate in human adrenocortical cancer: a preclinical study. J. Clin. Endocrinol. Metab. 101(12), 4594–4602 (2016)PubMedCrossRef
52.
S. Bornstein et al. Innovative multidimensional models in a high-throughput-format for different cell types of endocrine origin. p. 2022.01.10.475686 (2022)
53.
American Type Culture Collection Standards Development Organization Workgroup ASN-0002, Cell line misidentification: the beginning of the end. Nat. Rev. Cancer 10(6), 441–448 (2010)CrossRef
54.
L. Cerquetti et al. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocr. Relat. Cancer 15(2), 623–634 (2008)PubMedCrossRef
Metadata
Title
An update on adrenocortical cell lines of human origin
Authors
Sandra Sigala
Elisa Rossini
Andrea Abate
Mariangela Tamburello
Stefan R. Bornstein
Constanze Hantel
Publication date
28-06-2022
Publisher
Springer US
Published in
Endocrine / Issue 3/2022
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-022-03112-w

Other articles of this Issue 3/2022

Endocrine 3/2022 Go to the issue

Mini Review

Liquid biopsy for the assessment of adrenal cancer heterogeneity: where do we stand?

Original Article

Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life

Original Article

A systematic review of molecular alterations in invasive non-functioning pituitary adenoma

Original Article

Non-invasive follicular neoplasm with papillary-like nuclear features: a challenging and infrequent entity in Argentina

Mini Review

FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma

Original Article

Type-2 Diabetes Mellitus (T2DM): Spatial-temporal Patterns of Incidence, Mortality and Attributable Risk Factors from 1990 to 2019 among 21 World Regions
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits